Disclosures: Yu Rim Lee: Nothing to Disclose, Hyun Young Woo: Nothing to Disclose, Young Oh Kweon: Nothing to Disclose, Won Young Tak: Nothing to Disclose, Se Young Jang: Nothing to Disclose, Jung Gil Park: Nothing to Disclose, Min Kyu Kang: Nothing to Disclose, Jeong Eun Song: Nothing to Disclose, Jeong Heo: Gilead: Grant/Research Support, Roche: Speaking and Teaching, Roche: Speaking and Teaching, Yuhan: Speaking and Teaching, Abbvie: Speaking and Teaching, AstraZeneca: Advisor, Oncolys Japan: Grant/Research Support, Surrozen: Advisor, MedVir: Advisor, Jeong Hwa Lee: Nothing to Disclose, Min Hwa Park: Nothing to Disclose, Hyunyeol Lee: Nothing to Disclose, Soo Young Park: Nothing to Disclose 545 CHRONO-OPTIMAL TREATMENTS FOR HIV/HCV CO-INFECTION YIELD COMPARABLE SURVIVAL OUTCOMES WITH HCV MONO-INFECTION Jeayeon Park 1 Jae Yoon Jeong 2 Soon Sun Kim 3 Jae hyun Yoon 4 Hyuk Soo Eun 5 Jonggi Choi 6 Ki Tae Yoon 7 Young Kul Jung 8 Soo Young Park 9 Geum-Youn Gwak 10 Do Young Kim 11 Ji Hoon Kim 12 Jin-Woo Lee 13 Tae Yeob Kim 14 Jeong Won Jang 15 Su Jong Yu 1 , 1 Seoul national university hospital, 2 Ewha Womans University, Seoul, Korea, 3 Ajou University School of Medicine, Suwon, Korea, 4 Chonnam National University Hospital and College of Medicine, 5 Chungnam National University Hospital, 6 University of Ulsan, Asan Medical Center, 7 Pusan National University Yangsan Hospital, 8 Korea University Ansan Hospital, 9 Kyungpook National University School of Medicine, 10 Samsung Medical Center, 11 Severance Hospital, 12 Korea University Guro Hospital, 13 Inha University Hospital, 14 New Hope Internal Medicine Clinic, 15 Seoul St
Applied has now introduced another liquid carnitine product, although this one is a little more compact
Wong JC, Bathina M, Fiscus RR
To potentially move them into Category 1 or final Bulks List status, the most effective approach is to present a persuasive case for their clinical efficacy and safety to the Pharmacy Compounding Advisory Committee (PCAC) and submit it to the FDA
